ABSTRACT
Inflammatory bowel disease (IBD) is a chronic condition that significantly compromises the quality of life of patients. Biologicals have improved the course of the disease and its prognosis; however, not all patients have access to these treatments due to its high cost. Biosimilars seem to be a safe and effective option in the treatment of IBD. Because of its lower cost, the number of patients who have been treated increases every day. It is important to consider that not all patients respond to anti-TNF so alternatives have emerged within biological therapies that have demonstrated efficacy, and others are being tested. Antiintegrins emerge strongly as a new therapeutic model of IBD. With all these options probably the future treatment will be more personalized and less protocolized according to the characteristics of each patient.
La enfermedad inflamatoria intestinal (EII) es crónica y determina un notable compromiso de la calidad de vida de los pacientes que lo padecen. Los biológicos han mejorado el curso de la enfermedad y su pronóstico, sin embargo, no todos los pacientes tienen acceso a estos tratamientos debido a su alto costo. Los biosimilares parecen ser una opción segura y eficiente en el tratamiento de la EII. Debido a su menor costo cada día aumenta el número de pacientes que han sido tratados. Es importante considerar que no todos los pacientes responden a los anti TNF por lo que han surgido otras alternativas dentro de los biológicos que han demostrado eficacia y otros que se encuentran en evaluación. Los biológicos antiintegrinas surgen con fuerza como nuevo modelo terapéutico de las EII. Con todas estas alternativas es planteable que el tratamiento a futuro sea más personalizado y menos protocolizado según las características de cada paciente.
Subject(s)
Humans , Antibodies, Monoclonal/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Antibodies, Monoclonal, Humanized/therapeutic use , Colitis, Ulcerative/drug therapy , Crohn Disease/drug therapyABSTRACT
Behcet's disease is a chronic relapsing multisystemic inflammatory disorder characterized by four major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by five minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system symptoms). Although the etiology of Behcet's disease is still unknown, there have been recent advances in immunopathogenic studies, genome-wide association studies, animal models, diagnostic markers, and new biological agents. These advances have improved the clinical understanding of Behcet's disease and have enabled us to develop new treatment strategies for this intractable disease, which remains one of the leading causes of blindness.